Antileishmanial agent-43

Antileishmanial agent-43 (compound 4) (1-100 μM; 72 h) inhibits proliferation of Leishmania amazonensis promastigotes (IC₅₀ = 12.7 μM)^[1].
Antileishmanial agent-43 (0.1-100 μM; 48 h) suppresses growth of Leishmania amazonensis intracellular amastigotes (IC₅₀ = 0.96 μM)^[1].
Antileishmanial agent-43 (10-1000 μM; 48 h) exhibits low cytotoxicity against J774A.1 macrophages (CC₅₀ = 196.1 μM) and L929 fibroblasts (CC₅₀ = 232.1 μM)^[1].
Antileishmanial agent-43 (12.7 μM, 25.4 μM for promastigotes; 0.96 μM, 1.92 μM for amastigotes; 24 h) elevates ROS and nitric oxide levels, induces lipid peroxidation, triggers mitochondrial depolarization, disturbs ATP homeostasis, causes cell shrinkage, phosphatidylserine externalization, plasma membrane permeabilization, and promotes autophagic vacuole and acidic compartment formation in Leishmania amazonensis promastigotes and amastigotes^[1].
Antileishmanial agent-43 (12.7 μM, 25.4 μM for promastigotes; 0.96 μM, 1.92 μM for amastigotes; 72 h for promastigotes, 48 h for amastigotes) induces morphological and ultrastructural alterations in Leishmania amazonensis promastigotes and intracellular amastigotes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.